In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Ampliphi Biosciences (AMEX: APHB), with a price target of $3.50. The company’s shares opened today at $0.34, close to its 52-week low of $0.32.
Pantginis observed:
“Valuation and risks to price target achievement. We reiterate our Buy rating though are lowering our price target to $3.50 from $6. The factors contributing to our valuation change include: (1) adjustment to base year; (2) adjustment to fully diluted share count off of recent equity raise; and adjustment of our overall product projections with FDA visibility and guidance in hand now.”
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -12.0% and a 32.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ampliphi Biosciences with a $6 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.05 and a one-year low of $0.32. Currently, Ampliphi Biosciences has an average volume of 451.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AmpliPhi Biosciences Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company was founded in March 1989 and is headquartered in San Diego, CA.
